Mitochondrial Calcium Dysregulation and Targeted Therapies in Heart Failure — VialBase Research
Heart failure characterized by mitochondrial calcium dysregulation
- Heart failure characterized by mitochondrial calcium dysregulation
- SS-31/elamipretide discussed as targeted mitochondrial therapy
- Cardiolipin stabilization restores mitochondrial calcium handling
- Potential to improve cardiac energetics in HFrEF
PMID 41923743 — Mitochondrial Calcium in Heart Failure
Compound: SS-31 Citation: Liu M, Jin Y. Rev Cardiovasc Med. 2026;27(3):46211. doi:10.31083/RCM46211
Summary
Review of mitochondrial calcium dysregulation as a driver of heart failure pathology, with discussion of targeted therapies including elamipretide (SS-31).
Relevance to SS-31
SS-31’s cardiolipin stabilization has downstream effects on mitochondrial calcium handling. Dysregulated calcium -> mPTP opening -> cytochrome c release -> cardiomyocyte apoptosis. By preserving inner membrane integrity, SS-31 maintains calcium homeostasis and prevents cell death. This mechanism underpins the ongoing Phase 3 heart failure trials.
See Also
- Parent compound: SS-31
Save 15% with code VIALBASE
VialBase may earn a commission on partner links — never at extra cost to you. Disclosure.